BioCentury
ARTICLE | Clinical News

SCLN starts Phase II Zadaxin trial in melanoma

November 20, 2000 8:00 AM UTC

SciClone (SCLN) initiated a 20 patient Phase II trial in Australia using its Zadaxin thymosin alpha I immune modulator to treat malignant melanoma. Patients will receive an induction dose of Zadaxin a...